Wojtowicz-Praga S. Clinical potential ofmatrix metalloprotease inhibitors.
Drugs R D (New Zealand).1999;1:117 - 129.
Dupont E,Savard PE, Jourdain C, et al. Antiangiogenic properties of a novel sharkcartilage extract: Potential role in the treatment of psoriasis.
JCutan Med Surg. 1998;2:146 - 152.
Sheu JR, Fu CC, Tsai ML, et al. Effect ofU-995, a potent shark cartilage-derived angiogenesis inhibitor, onanti-angiogenesis and anti-tumor activities.
Anticancer Res.1998;18:4435 - 4441.
DavisPF, He Y, Furneaux RH, et al. Inhibition of angiogenesis by oral ingestion ofpowdered shark cartilage in a rat model.
Microvasc Res.1997;54:178 - 182.
Oikawa T,Ashino-Fuse H, Shimamura M, et al. A novel angiogenic inhibitor derived fromJapanese shark cartilage (I). Extraction and estimation of inhibitoryactivities toward tumor and embryonic angiogenesis.
CancerLett. 1990;51:181 - 186.
McGuire TR, Kazakoff PW, Hoie EB, et al.Antiproliferative activity of shark cartilage with and without tumor necrosisfactor-alpha in human umbilical vein endothelium.
Pharmacotherapy. 1996;16:237 - 244.
Lee A, Langer R. Shark cartilage containsinhibitors of tumor angiogenesis.
Ciencia. 1983;221:1185 - 1187.
Riviere M, Latreille J,Falardeau P, et al. AE-941 (Neovastat), an inhibitor of angiogenesis: phaseI/II cancer clinical trial results.
Cancer Invest.1999;17(suppl 1):16 - 17.
Jamali M-A, Riviere M, Falardeau P, et al. Effect of AE-941(neovastat), an angiogenesis inhibitor, in the Lewis lung carcinoma metastaticmodel, efficacy, toxicity prevention and survival.
Clin InvestMed. 1998;Suppl:S16.
Riviere M, Falardeau P, Latreille J, etal. Phase I/II lung cancer clinical trial results with AE-941 (neovastat), aninhibitor of angiogenesis.
Clin Invest Med. 1998;Suppl:S14.
Riviere M, Alaoui-JamaliM, Falardeau P, et al. Neovastat: an inhibitor of angiogenesis with anti-canceractivity. Presented at: American Association for Cancer Research Annual Meeting39; March 28 - April 1, 1998; New Orleans, La.
Blasecki J, Alaoui-Jamali M, Wang T, etal. Oral administration of Neovastat inhibits tumor progression in animalmodels of progressive tumor growth and metastasis.
Int JOncol. 1997;11(suppl):934.
Dupont E, Alaoui-Jamali M, Wang T, et al.
Angiostatic and antitumoral activity of AE-941 (Neovastat), a molecularfraction derived from shark cartilage. Presented at: AmericanAssociation for Cancer Research Annual Meeting 38; April 12 - 16, 1997; SanDiego, Calif.
HorsmanMR, Alsner J, Overgaard J. The effect of shark cartilage extracts on the growthand metastatic spread of the SCCVII carcinoma.
Acta Oncol.1998;37:441 - 445.
MillerDR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacyof shark cartilage in the treatment of advanced cancer.
J ClinOncol. 1998;16:3649 - 3655.
Gellert GA, Maxwell RM, Siegel BS.Survival of breast cancer patients receiving adjunctive psychosocial supporttherapy: a 10-year follow-up study.
J Clin Oncol.1993;11:66 - 69.
MausellE, Brisson J, Deschênes L. Social support and survival among women with breastcancer.
Cancer. 1995;76:631 - 637.
Spiegel D, Bloom JR, Kraemer HC, GottheilE. Effect of psychosocial treatment on survival of patients with metastaticbreast cancer.
Lancet. 1989;2:888 - 891.
Cameron E, Pauling L. Supplementalascorbate in the supportive treatment of cancer: Prolongation of survival timesin terminal human cancer.
Proc Natl Acad Sci U S A.1976;73:3685 - 3689.
Cameron E, Campbell A. Innovation vs. quality control: an"unpublishable" clinical trial of supplemental ascorbate in incurable cancer.
Med Hypotheses. 1991;36:185 - 189.
Murata A, Morishige F, Yamaguchi H.Prolongation of survival times of terminal cancer patients by administration oflarge doses of ascorbate.
Int J Vit Nutr Res Suppl.1982;23:103 - 113.
CreaganET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbicacid) therapy to benefit patients with advanced cancer. A controlled trial.
N Engl J Med. 1979;301:687 - 690.
Moertel CG, Fleming TR, Creagan ET, etal. High-dose vitamin C versus placebo in the treatment of patients withadvanced cancer who have had no prior chemotherapy. A randomized double-blindcomparison.
N Engl J Med. 1985;312:137 - 141.
Lissoni P, Meregalli S, Nosetto L, et al.Increased survival time in brain glioblastomas by a radioneuroendocrinestrategy with radiotherapy plus melatonin compared to radiotherapy alone.
Oncology. 1996;53:43 - 46.
Lissoni P, Paolorossi F, Ardizzoia A, etal. A randomized study of chemotherapy with cisplatin plus etoposide versuschemoendocrine therapy with cisplatin, etoposide and the pineal hormonemelatonin as a first-line treatment of advanced non-small cell lung cancerpatients in a poor clinical state.
J Pineal Res.1997;23:15 - 19.
Neri B,de Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier incancer patients.
Anticancer Res. 1998;18:1329 - 1332.
Cos S, Fernández R,Güézmes A, Sánchez-Barceló EJ. Influence of melatonin on invasive andmetastatic properties of MCF-7 human breast cancer cells.
CancerRes. 1998;58:4383 - 4390.
Lissoni P, Barmo S. Meregalli S, et al.Modulation of cancer endocrine therapy by melatonin: a phase II study oftamoxifen plus melatonin in metastatic breast cancer patients progressing undertamoxifen alone.
Br J Cancer. 1995;71:854 - 856.
Lissoni P, Cazzanga M,Tancini G, et al. Reversal of clinical resistance to LHRH analogue inmetastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRHanalogue plus melatonin in patients progressing on LHRH analogue alone.
Eur Urol. 1997;31:178 - 181.
Lockwood K, Moesgaard S, Hanioka T,Folkers K. Apparent partial remission of breast cancer in "high risk" patientssupplemented with nutritional antioxidants, essential fatty acids and coenzymeQ
10.
Molec Aspects Med Suppl.1994;5:S231 - S240.
Lockwood K, Moesgaard S, Folkers K. Partial and complete regressionof breast cancer in patients in relation to dosage of coenzymeQ
10.
Biochem Biophys Res Comm.1994;199:1504 - 1508.
Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapyof breast cancer with vitamin Q
10
and the regression ofmetastases.
Biochem Biophys Res Comm. 1995;212:172 - 177.
Rudra PK, Krokan HE.Cell-specific enhancement of doxorubicin toxicity in human tumour cells bydocosahexaenoic acid.
Anticancer Res.2001;21:29-38.
Kucuk O,Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopenesupplementation before radical prostatectomy.
Cancer EpidemiolBiomarkers Prev. 2001;10:861 - 868.
Hauns B, Haring B, Kohler S, et al. PhaseII study with 5-fluorouracil and Ginkgo biloba extract (GBE 761 ONC) inpatients with pancreatic cancer.
Arzneimittelforschung.1999;49:1030 - 1034.
DudaRB, Zhong Y, Navas V, et al. American ginseng and breast cancer therapeuticagents synergistically inhibit MCF-7 breast cancer cell growth.
J SurgOncol. 1999;72:230 - 239.
Gvamichava AR, Khatiashvili TM,Khudzhadze RG, et al. First results of the use of Eleutherococcus in thecombined treatment of breast carcinoma.
Lek Sredestva Dal'negoVostoka. 1966;7:231 - 235.
Kupin VI, Polevaia YeB, Sorokin AM.Stimulation of the immunological reactivity of cancer patients byEleutherococcus extract.
Vopr Onkol. 1986;32:21 - 26.
Kiene H, Buschel G,Hornebar M. et al. Mistletoe or not mistletoe is still the question.
Forsch Komplementarmed Klass Naturheilkd.2001;8:309 - 312.
GoebellPJ, Otto T, Suhr J, Rubben H. Evaluation of an unconventional treatmentmodality with mistletoe lectin to prevent recurrence of superficial bladdercancer: a randomized phase II trial.
J Urol. 2002;168:72 - 75.
Kleijnen J, KnipschildP. Mistletoe treatment for cancer. Review of controlled trials in humans.
Phytomedicine. 1994;1:255 - 260.
McNamee D. Mistletoe extract ineffectivein melanoma.
Lancet. 1999;354:1101.
Lenartz D, Dott U, Menzel J, SchierholzJM, Beuth J. Survival of glioma patients after complementary treatment withgalactoside-specific lectin from mistletoe.
Anticancer Res.2000;20:2073 - 2076.
Stauder H, Kreuser ED. Mistletoe extracts standardised in terms ofmistletoe lectins (ML I) in oncology: current state of clinical research.
Onkologie. 2002;25:374 - 380.
Steuer-Vogt MK, Bonkowsky V, Ambrosch P,et al. The effect of an adjuvant mistletoe treatment programme in resected headand neck cancer patients: a randomised controlled clinical trial.
Eur JCancer. 2001;37:23 - 31.
Heiny BM. Adjuvant treatment withstandardized mistletoe extract reduces leukopenia and improves the quality oflife of patients with advanced carcinoma of the breast receiving palliativechemotherapy (VEC regimen).
Krebsmedizin. 1991;12:3 - 14.
Harvey J, Colin-JonesDG. Mistletoe hepatitis.
Br Med J (Clin Res Ed).1981;282:186-187.
VanVeldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin Ddeficiency in patients with metastatic prostate cancer may improve bone painand muscle strength.
J Urol. 2000;163:187 - 190.
van Zandwijk N, DalesioO, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A andN-acetylcysteine in patients with head and neck cancer or lung cancer.
J Natl Cancer Inst. 2000;92:977 - 986.
Bruera E, Strasser F, Palmer JL, et al.Effect of fish oil on appetite and other symptoms in patients with advancedcancer and anorexia/cachexia: a double-blind, placebo-controlled study.
J Clin Oncol. 2003;21:129 - 134.
Sovak M, Seligson AL, Konas M, et al.PC-SPES in prostate cancer: an herbal mixture currently containing warfarin andpreviously diethylstilbestrol and indomethacin. Presented at: 93rd AnnualMeeting of the American Association for Cancer Research; April 6 - 10, 2002; SanFrancisco, CA.
DanieleB, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracilinduced intestinal toxicity: a double blind, placebo controlled, randomisedtrial.
Gut. 2001;48:28 - 33.
Unger C, Haring B, Kruse A, et al.Double-blind randomised placebo-controlled phase III study of an E. coliextract plus 5-fluorouracil versus 5-fluorouracil in patients with advancedcolorectal cancer.
Arzneimittelforschung. 2001;51:332 - 338.
Carl W, Emrich LS.Management of oral mucositis during local radiation and systemic chemotherapy:A study of 98 patients.
J Prosthet Dent. 1991;66:361 - 369.
Fidler P, Loprinzi CL,O'Fallon JR, et al. Prospective evaluation of a chamomile mouthwash forprevention of 5-FU-induced oral mucositis.
Cancer.1996;77:522 - 525.
MillsEED. The modifying effect of beta-carotene on radiation and chemotherapyinduced oral mucositis.
Brit J Cancer. 1988;57:416 - 417.
Wadleigh RG, Redman RS,Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis.
Am J Med. 1992;92:481 - 484.
Meyer K, Schwartz J, Crater D, et al.Zingiber officinale (ginger) used to prevent 8-Mop associated nausea.
Dermatol Nurs. 1995;7:242 - 244.
Playford RJ, Macdonald CE, Johnson WS.Colostrum and milk-derived peptide growth factors for the treatment ofgastrointestinal disorders.
Am J Clin Nutr. 2000;72:5 - 14.
Zeltzer LK, Dolgin MJ,LeBaron S, et al. A randomized, controlled study of behavioral intervention forchemotherapy distress in children with cancer.
Pediatrics.1991;88:34 - 42.
SyrjalaKL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for thereduction of pain and nausea during cancer treatment: a controlled clinicaltrial.
Pain. 1992;48:137 - 146.
Lyles JN, Burish TG, Krozely MG, et al.Efficacy of relaxation training and guided imagery in reducing the aversivenessof cancer chemotherapy.
J Consult Clin Psychol.1982;50:509 - 524.
TroeschLM, Rodehaver CB, Delaney EA, Yanes B. The influence of guided imagery onchemotherapy-related nausea and vomiting.
Oncol Nurs Forum.1993;20:1179 - 1185.
Syrjala KL, Donaldson GW, Davis MW, et al. Relaxation and imageryand cognitive-behavioral training reduce pain during cancer treatment: acontrolled clinical trial.
Pain. 1995;63:189 - 198.
Troesch LM, RodehaverCB, Delaney EA, Yanes B. The influence of guided imagery onchemotherapy-related nausea and vomiting.
Oncol Nurs Forum.1993;20:1179 - 1185.
SpecaM, Carlson LE, Goodey E, et al. A randomized, wait-list controlled clinicaltrial: the effect of a mindfulness meditation-based stress reduction program onmood and symptoms of stress in cancer outpatients.
PsychosomMed. 2000;62:613 - 622.
Zeltzer L, LeBaron S. Hypnosis andnonhypnotic techniques for reduction of pain and anxiety during painfulprocedures in children and adolescents with cancer.
J Pediatr.1982;101:1032 - 1035.
Walker LG, Walker MB, Ogston K, et al. Psychological, clinical andpathological effects of relaxation training and guided imagery during primarychemotherapy.
Br J Cancer. 1999;80:262 - 268.
Baider L, Peretz T, Hadani PE, Koch U.Psychological intervention in cancer patients: a randomized study.
GenHosp Psychiatry. 2001;23:272 - 277.
Holoya PY, Duelge J, Hansen RM,.Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
SemOncol. 1983;10(Suppl 1):66 - 71.
Slavik M, Saiers JH. Phase I clinicalstudy of acetylcysteine's preventing ifosfamide-induced hematuria.
SemOncol. 1983;10(suppl 1):62 - 65.
Loehrer PJ, Williams SD, Einhorn LH.N-Acetylcysteine and ifosfamide in the treatment of unresectable pancreaticadenocarcinoma and refractory testicular cancer.
Sem Oncol.1983;10(Suppl 1):72 - 75.
Morgan LR, Donley PJ, Harrison EF. The control of ifosfamide induced hematuriawith N-acetylcysteine.
Proc Am Assoc Cancer Res. 1981;22:190.
De Blasio F, et al.N-acetyl cysteine (NAC) in preventing nausea and vomiting induced bychemotherapy in patients suffering from inoperable non small cell lung cancer(NSCLC).
Chest. 1996;110(Suppl 4):103S.
Hardman WE, Moyer MP, Cameron IL.Consumption of an omega-3 fatty acids product, INCELL AAFA, reducedside-effects of CPT-11 (irinotecan) in mice.
Br J Cancer.2002;86:983-989.
LissoniP, Tancini G, Barni S, et al. Treatment of cancer chemotherapy-induced toxicitywith the pineal hormone melatonin.
Support Care Cancer.1997;5:126 - 129.
LissoniP, Barni S, Mandalà, et al. Decreased toxicity and increased efficacy of cancerchemotherapy using the pineal hormone melatonin in metastatic solid tumourpatients with poor clinical status.
Eur J Cancer.1999;35:1688 - 1692.
CombsAB, Choe JY, Truong DH, et al. Reduction by coenzyme Q
10
of the acute toxicity of adriamycin in mice.
Res Commun Chem PatholPharmacol. 1977;18:565 - 568.
Judy WV, Hall JH, Dugan W, et al.Coenzyme Q
10
reduction of Adriamycin cardiotoxicity.
Biomed Clin Aspects Coenzyme Q.1984;4:231 - 241.
SugiyamaS, Yamada K, Hayakawa M, et al. Approaches that mitigate doxorubicin-induceddelayed adverse effects on mitochondrial functions in rat hearts;Liposome-encapsulated doxorubicin or combination therapy with antioxidant.
Biochem Mol Biol Int. 1995;36:1001 - 1007.
Legha SS, Wang YM, Mackay B, et al.Clinical and pharmacologic investigation of the effects of alpha-tocopherol onAdriamycin cardiotoxicity.
Ann NY Acad Sci.1982;393:411 - 418.
Gaedeke J, Fels LM, Bokemeyer C, et al. Cisplatin nephrotoxicity and protectionby silibinin.
Nephrol Dial Transplant. 1996;11:55 - 62.
Urbancsek H, Kazar T,Mezes I, et al. Results of a double-blind, randomized study to evaluate theefficacy and safety of Antibiophilus in patients with radiation-induceddiarrhoea.
Eur J Gastroenterol Hepatol. 2001;13:391 - 396.
Olsen DL, Raub W Jr,Bradley C, et al. The effect of aloe vera gel/mild soap versus mild soap alonein preventing skin reactions in patients undergoing radiation therapy.
Oncol Nurs Forum. 2001;28:543 - 547.
Heggie S, Bryant GP, Tripcony L, et al. Aphase III study on the efficacy of topical aloe vera gel on irradiated breasttissue.
Cancer Nurs. 2002;25:442 - 451.
Maiche AG, Grohn P, Maki-Hokkonen H.Effect of chamomile cream and almond ointment on acute radiation skin reaction.
Acta Oncol. 1991;30:395 - 396.
Ripamonti C, Zecca E, Brunelli C, et al.A randomized, controlled clinical trial to evaluate the effects of zinc sulfateon cancer patients with taste alterations caused by head and neck irradiation.
Cancer. 1998;82:1938 - 1945.
Martin T, Uhder K, Kurek R, et al. Doesprophylactic treatment with proteolytic enzymes reduce acute toxicity ofadjuvant pelvic irradiation? Results of a double-blind randomized trial.
Radiother Oncol. 2002;65:17 - 22.
Jacobson JS, Troxel AB, Evans J, et al.Randomized trial of black cohosh for the treatment of hot flashes among womenwith a history of breast cancer.
J Clin Oncol.2001;19:2739 - 2745.
VanPatten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hotflashes in postmenopausal women with breast cancer: a randomized, controlledclinical trial.
J Clin Oncol. 2002;20:1449 - 1455.
Quella SK, Loprinzi CL,Barton DL. Evaluation of soy phytoestrogens for the treatment of hot flashes inbreast cancer survivors: A North Central Cancer Treatment Group Trial.
J Clin Oncol. 2000;18:1068 - 1074.
Amato P, Christophe S, Mellon P.Estrogenic activity of herbs commonly used as remedies for menopausal symptoms.
Menopause. 2002;9:145 - 150.
Lippman M, Monaco ME, Bolan G. Effects ofestrone, estradiol and estriol on hormone-responsive human breast cancer inlong-term tissue culture.
Cancer Res. 1977;37:1901 - 1907.
Labriola D, LivingstonR. Possible interactions between dietary antioxidants and chemotherapy.
Oncology. 1999;13:1003 - 1012.
Weijl NI, Cleton FJ, Osanto S. Freeradicals and antioxidants in chemotherapy-induced toxicity.
CancerTreat Res. 1997;23:209 - 240.
Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemo-endocrine Therapy for Breast Cancer (ACETBC) of Japan.
Eur J Cancer. 1996;32A:235 - 242.
Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Lancet. 1994;343:1122 - 1126.
Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer.
Cancer Immunol Immunother. 1990;31:261 - 268.
Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
Cancer. 1992;70:2475 - 2483.
Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Dis Colon Rectum. 1992;35:123 - 130.
Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.
Anticancer Res. 1995;15:2907 - 2912.
Borghardt J, Rosien B, Gortelmeyer R, et al. Effects of a spleen peptide preparation as supportive therapy in inoperable head and neck cancer patients.
Arzneimittelforschung. 2000;50:178 - 184.
Weitzman S. Alternative nutritional cancer therapies. Int J Cancer Suppl. 1998;11:69 - 72.104. Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy.
Gynecol Oncol. 2003;88:434 - 439.
Último revisado julio 2012 por EBSCO CAM Review Board
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.
Copyright © EBSCO Publishing. All rights reserved.